Vaxcyte, Inc. $PCVX Shares Purchased by T. Rowe Price Investment Management Inc.

T. Rowe Price Investment Management Inc. grew its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 35.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,296,333 shares of the company’s stock after buying an additional 2,981,038 shares during the quarter. T. Rowe Price Investment Management Inc. owned about 0.09% of Vaxcyte worth $521,213,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in the stock. Smartleaf Asset Management LLC boosted its holdings in shares of Vaxcyte by 156.2% in the fourth quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock valued at $27,000 after acquiring an additional 364 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its stake in shares of Vaxcyte by 1,463.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock valued at $30,000 after acquiring an additional 600 shares during the period. EverSource Wealth Advisors LLC raised its holdings in Vaxcyte by 33.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after purchasing an additional 184 shares in the last quarter. Allworth Financial LP raised its holdings in Vaxcyte by 148.9% during the third quarter. Allworth Financial LP now owns 1,222 shares of the company’s stock worth $44,000 after purchasing an additional 731 shares in the last quarter. Finally, Aster Capital Management DIFC Ltd acquired a new stake in Vaxcyte in the third quarter worth approximately $45,000. 96.78% of the stock is owned by institutional investors and hedge funds.

Vaxcyte Price Performance

NASDAQ PCVX opened at $51.44 on Friday. Vaxcyte, Inc. has a 12 month low of $29.08 and a 12 month high of $65.00. The company has a market capitalization of $7.43 billion, a P/E ratio of -7.48 and a beta of 1.24. The company’s 50 day simple moving average is $53.56 and its 200 day simple moving average is $52.70.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Wednesday, May 6th. The company reported ($2.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same period in the previous year, the company posted ($1.04) EPS. On average, analysts anticipate that Vaxcyte, Inc. will post -7.56 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Grant Pickering sold 2,000 shares of Vaxcyte stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $52.50, for a total value of $105,000.00. Following the transaction, the chief executive officer directly owned 135,215 shares in the company, valued at $7,098,787.50. The trade was a 1.46% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $49.52, for a total value of $111,420.00. Following the sale, the chief operating officer directly owned 158,494 shares in the company, valued at $7,848,622.88. This trade represents a 1.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 41,961 shares of company stock valued at $2,233,490. 3.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on PCVX shares. BTIG Research increased their price target on Vaxcyte from $85.00 to $89.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a research note on Wednesday, April 8th. Jefferies Financial Group restated a “buy” rating on shares of Vaxcyte in a report on Tuesday, March 10th. Finally, Wall Street Zen cut Vaxcyte from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 28th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $86.00.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.